Key clinical point: Lisocabtagene maraleucel (liso-cel), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy, has demonstrated manageable toxicity and promising clinical activity in heavily pretreated patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
Major finding: The overall response rate was 81.5%, with 8 of 12 responding patients still in response for a year or longer.
Study details: Phase 1 results of an ongoing study including 23 patients with CLL/SLL who have failed ibrutinib and at least one other line of therapy.
Disclosures: Dr. Siddiqi reported disclosures related to Kite, TG Therapeutics, Celgene, Janssen, Seattle Genetics, AstraZeneca, PCYC, Juno Therapeutics, and BeiGene.
Siddiqi T et al. ASH 2019,.